Immatics N.V. IMTX, +2.97% shares gained over 8% on Monday premarket after the clinical-stage company announced it received a 35 million equity investment by Bristol Myers Squibb Co. BMY, +0.87% . In a private placing, Immatics stated that the pharmaceutical giant bought more than 2,4 million Immatics share at a price per share of $14.46. Bristol Myers Squibb also has the right to nominate a member of the Immatics Scientific Advisory Board, according to the press release. Immatics focuses on the discovery and development T cell-redirecting immunotherapies for cancer. Bristol Myers Squibb’s shares rose 0.3% in premarket trading on Monday. They have fallen 10.1% this year, while the S&P500 SPX +0.37% has risen 18%.